Newsletter | July 25, 2024

07.25.24 -- Using The ADKAR Model In Biopharma Change Management

SPONSOR

Connect science and compliance at the 19th annual PDA Pharmaceutical Microbiology Conference, October 7 - 9 in Washington, DC, and navigate the crucial nexus between scientific advancement and regulatory adherence! Don’t miss out on directly interacting with the experts, poster presentations, and the Exhibit Hall where leading companies will showcase the latest technologies, equipment, and applications. This conference sells out quickly! View the agenda and register today.

FEATURED EDITORIAL

Using The ADKAR Model In Biopharma Change Management

Biopharma companies dedicated to continuous improvement are the ones that dominate their market sector. Using the ADKAR model of change management can help.

INDUSTRY INSIGHTS

Mycoplasma Contamination In Biopharmaceutical Manufacturing

Learn how following strict laboratory practices and conducting routine testing for mycoplasma contamination using nucleic acid-based assays can help ensure the production of safe and high-quality biopharmaceutical products.

How To Ensure Correct Component Selection When Outsourcing To A CMO

What happened when a growing biopharmaceutical company discovered a CMO-recommended lyophilization stopper was contributing to several operational inefficiencies, including sticking and interlocking of stoppers during filling operations?

 

Evaluating The Impact Of Sterilization Methods On Stopper Performances

Three studies cover a product that aims to address unmet needs around the development of subcutaneous drug therapies for chronic disease treatment, including methods for sterilization and a Human Factors evaluation.

NEWS HEADLINES

Fresenius Announces EMA Validation Of Marketing Authorization Application For Denosumab Biosimilar Candidates

Xbrane Provides Update On Its Development Portfolio

Boehringer Ingelheim & GoodRx Announce Exclusive Patient Affordability Initiative For Adalimumab-adbm Injection, Boehringer's Biosimilar To Humira

Analysis Finds Misinformation About Interchangeable Biosimilars Undermining U.S. Health Policy, Physician Confidence, & Patient Health

SOLUTIONS

Be A Gain Changer, 2x Throughput, Only With Supor Prime